Asthma Clinical Trial
— HAP3Official title:
Clinic Navigation and Home Visits to Improve Guideline-based Care and Outcomes in Low Income Minority Adults With Asthma
| Verified date | September 2023 |
| Source | University of Pennsylvania |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Asthma-related deaths are more numerous among low-income minority patients and older adults with chronic diseases. Guidelines for asthma management have not addressed the needs of these groups. The investigators recently demonstrated the feasibility, acceptability, and evidence of effectiveness of two interventions to improve access to care, patient-provider communication, and asthma outcomes: 1) CI: clinic intervention using a patient advocate to prepare for, attend, and confirm understanding of an office visit, and 2) HV: home visits for care coordination and informing clinicians of home barriers to managing asthma is associated with subsequent improvement in asthma outcomes. This project explores whether these interventions can be combined for greater effectiveness, delivery of guideline-based asthma care, and outcomes in low-income minority patients. In a randomized controlled factorial trial, 400 adults with uncontrolled asthma living in low-income urban neighborhoods are offered 18-months' participation: 12 months of clinical intervention and 6 months of evaluation to monitor sustainability of interventions and outcomes. Patients will be randomized to 1) a patient advocate and (2) an advocate and home visits, (3) an advocate and real-time feedback to the asthma provider (clinician) at each clinic visit of guidelines-relevant relevant information, and 4) (2), and (3). Interventions will be delivered by a community health worker. The study estimates Specific Aim 1: improvement over time of within-group (before-after in four groups) asthma outcomes (asthma control, quality of life, ED visits, hospitalizations, prednisone bursts) Specific Aim 2: across group differences in improvement over time in asthma outcomes; Specific Aim 3: the costs associated with each of the interventions. A cost-offset analysis will determine which intervention costs are offset by savings attributable to reductions in ED, hospitalization or other visits for asthma control and other outcomes. Exploratory Aim: changes in behavior from the interventions using interviews of clinicians and patients. Investigators hypothesize that improved outcomes in asthma patients will result from enhanced patient-clinician communication, clinician attention to home environmental exposures, and clinician consideration of the guidelines, at a program cost offset by lower patient health care utilization.
| Status | Active, not recruiting |
| Enrollment | 367 |
| Est. completion date | April 30, 2025 |
| Est. primary completion date | December 31, 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Female or male > 18 years and living in a Philadelphia neighborhood in which at least 20% of households have incomes below the federal poverty level (19104, 19120, 19121, 19122, 19124, 19125, 19131, 19132, 19133, 19134, 19139, 19140, 19141, 19142, 19143, 19144, 19145, 19146, 19153, 19151) - A patient in a participating clinic - Doctor's diagnosis of asthma - Prescribed an inhaled corticosteroid for asthma - Required prednisone or an Emergency Department (ED) visit or hospitalization for asthma within 12 months before enrollment. - Some patients with a diagnosis of asthma and prescribed inhaled corticosteroid may also have mention of Chronic Obstructive Pulmonary Disease (COPD) in their record, particularly if they smoke. Asthma and COPD are both heterogeneous diseases, and may be impossible to distinguish by clinical characteristics.Both COPD and asthma can have evidence of reversible obstruction and also of irreversible obstruction. It is important not to exclude these patients, sometimes called overlap patients as they may benefit from these interventions. Exclusion Criteria: - Severe psychiatric or cognitive problems making it impossible to understand or carry out the protocol; - Excluded are those with other chronic lung diseases: lung cancer, cystic fibrosis, heart failure, chronic bronchitis, pulmonary hypertension, a candidate or recipient for lung transplant, a history of bronchial thermoplasty. Excluded are those with more than 20 pack year tobacco use. |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Pennsylvania Health Center | Philadelphia | Pennsylvania |
| United States | University of Pennsylvania Health System | Philadelphia | Pennsylvania |
| Lead Sponsor | Collaborator |
|---|---|
| University of Pennsylvania | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Asthma Control at baseline | Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control | At randomization | |
| Primary | Asthma Control at 3 months | Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control | 3 months | |
| Primary | Asthma Control at 6 months | Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control | 6 months | |
| Primary | Asthma Control at 9 months | Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control | 9 months | |
| Primary | Asthma Control at 12 months | Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control | 12 months | |
| Primary | Asthma Control at 15 months | Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control | 15 months | |
| Primary | Asthma Control at 18 months | Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control | 18 months | |
| Secondary | hospitalizations for asthma | number of hospitalizations as indicated in the electronic medical record. If no record is available, the patient's report and verified if possible with patients' record from the outside institution will be used | hospitalizations at 3 months | |
| Secondary | hospitalizations for asthma | Number of hospitalizations as indicated in the electronic medical record. If no record is available, patient's report and verified if possible with patients' record from the outside institution will be used. | hospitalizations at 6 months | |
| Secondary | hospitalizations for asthma | Number of hospitalizations as indicated in the electronic medical record. If no record is available, patient's report and verified if possible with patients' record from the outside institution will be used. | hospitalizations at 9 months | |
| Secondary | hospitalizations for asthma | Number of hospitalizations as indicated in the electronic medical record. If no record is available, patient's report and verified if possible with patients' record from the outside institution will be used. | hospitalizations at 12 months | |
| Secondary | hospitalizations for asthma | Number of hospitalizations as indicated in the electronic medical record. If no record is available, patient's report and verified if possible with patients' record from the outside institution will be used. | hospitalizations at 15 months | |
| Secondary | hospitalizations for asthma | Number of hospitalizations as indicated in the electronic medical record. If no record is available, patient's report and verified if possible with patients' record from the outside institution will be used.patient's report and verified if possible with patients' record from the outside institution | hospitalizations at 18 months | |
| Secondary | Emergency Department (ED) visits for asthma | Number of ED visits as indicated in the electronic medical record. If no record is available patient's report and verified if possible with patients' record from the outside institution will be used. | 3 months | |
| Secondary | Emergency Department (ED) visits for asthma | Number of ED visits as indicated in the electronic medical record. If no record is available patient's report and verified if possible with patients' record from the outside institution will be used. | 6 months | |
| Secondary | Emergency Department (ED) visits for asthma | Number of ED visits as indicated in the electronic medical record. If no record is available patient's report and verified if possible with patients' record from the outside institution will be used. | 9 months | |
| Secondary | Emergency Department (ED) visits for asthma | Number of ED visits as indicated in the electronic medical record. If no record is available patient's report and verified if possible with patients' record from the outside institution will be used. report and verified if possible with patients' record from the outside institution | 12 months | |
| Secondary | Emergency Department (ED) visits for asthma | Number of ED visits as indicated in the electronic medical record. If no record is available patient's report and verified if possible with patients' record from the outside institution will be used. | 15 months | |
| Secondary | Emergency Department (ED) visits for asthma | Number of ED visits as indicated in the electronic medical record. If no record is available patient's report and verified if possible with patients' record from the outside institution will be used. | 18 months | |
| Secondary | asthma-related quality of life | Score is the mean of the 15-items each scored 1-7. Higher score indicates better quality of life. | 3 months | |
| Secondary | asthma-related quality of life | Score is the mean of the 15-items each scored 1-7. Higher score indicates better quality of life. | 6 months | |
| Secondary | asthma-related quality of life | Score is the mean of the 15-items each scored 1-7. Higher score indicates better quality of life. | 9 months | |
| Secondary | asthma-related quality of life | Score is the mean of the 15-items each scored 1-7. Higher score indicates better quality of life. | 12 months | |
| Secondary | asthma-related quality of life | Score is the mean of the 15-items each scored 1-7. Higher score indicates better quality of life. | 15 months | |
| Secondary | asthma-related quality of life | Score is the mean of the 15-items each scored 1-7. Higher score indicates better quality of life. | 18 months | |
| Secondary | Forced expiratory volume in 1 second (FEV1) | forced vital capacity in 1 second | Month 12 | |
| Secondary | Forced expiratory volume in 1 second (FEV1) | forced vital capacity in 1 second | Month 18 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|